Related Experiment Video
Updated: Apr 4, 2026

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
Published on: September 22, 2023
Nanoparticle-Based Targeted Drug Delivery Systems for Allergic Rhinitis: A Comprehensive Review
Yuenan Wang1, Yang Zhou2,3, Boshen Liang4
1Basic Medical College, Yunnan University of Chinese Medicine, Kunming, Yunnan, People's Republic of China.
None:
Allergic rhinitis (AR) is an immunoglobulin E (IgE)-mediated immune response triggered by inhaled allergens, primarily involving type 2 cell-driven nasal mucosal inflammation. Current clinical management of AR relies on pharmacotherapy and immunomodulatory therapies but is limited by treatment time windows, bioavailability, and side effects. Rational design of nanodrug carriers can enhance drug bioavailability and enable targeted delivery. Nanoparticles (NPs) transport drugs or gene fragments to nasal tissues via passive or active targeting, thereby improving therapeutic efficacy while minimizing damage to healthy tissues. This review summarizes recent applications of NPs in preclinical and clinical AR treatment, highlighting strategies for targeted therapy using nanodrugs. It discusses the benefits and mechanisms of innovative drug delivery systems in the treatment of AR and provides a comprehensive catalog of such systems. Finally, it outlines future prospects for improved clinical translation.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Allergic Reactions: Anaphylaxis
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Allergic Drug Reactions

